Parallel Advisors LLC Sells 3,354 Shares of IQVIA Holdings Inc. $IQV

Parallel Advisors LLC cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 37.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,521 shares of the medical research company’s stock after selling 3,354 shares during the quarter. Parallel Advisors LLC’s holdings in IQVIA were worth $870,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC boosted its position in IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after buying an additional 2,537 shares during the period. State of Wyoming boosted its position in IQVIA by 52.5% during the 4th quarter. State of Wyoming now owns 851 shares of the medical research company’s stock worth $167,000 after buying an additional 293 shares during the period. Waverly Advisors LLC acquired a new stake in IQVIA during the 4th quarter worth approximately $626,000. Voloridge Investment Management LLC boosted its position in IQVIA by 325.7% during the 4th quarter. Voloridge Investment Management LLC now owns 194,103 shares of the medical research company’s stock worth $38,143,000 after buying an additional 148,512 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in IQVIA by 13.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,393,140 shares of the medical research company’s stock worth $273,766,000 after buying an additional 167,057 shares during the period. 89.62% of the stock is owned by institutional investors.

IQVIA Price Performance

Shares of NYSE:IQV opened at $190.17 on Friday. The company’s 50-day moving average is $184.30 and its 200 day moving average is $167.42. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market capitalization of $32.33 billion, a P/E ratio of 27.52, a price-to-earnings-growth ratio of 2.05 and a beta of 1.32. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $248.03.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. The company had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analysts Set New Price Targets

IQV has been the subject of several analyst reports. William Blair restated an “outperform” rating on shares of IQVIA in a report on Wednesday, July 23rd. Jefferies Financial Group upgraded shares of IQVIA from a “hold” rating to a “buy” rating and raised their price target for the stock from $195.00 to $225.00 in a report on Tuesday, September 9th. Redburn Partners set a $214.00 price target on shares of IQVIA in a report on Wednesday, September 3rd. Truist Financial lifted their price objective on shares of IQVIA from $209.00 to $235.00 and gave the company a “buy” rating in a research note on Wednesday, July 23rd. Finally, Robert W. Baird lifted their price objective on shares of IQVIA from $159.00 to $196.00 and gave the company a “neutral” rating in a research note on Wednesday, July 23rd. Eighteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $229.64.

Insider Activity

In other news, insider Keriann Cherofsky sold 549 shares of the company’s stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider directly owned 2,910 shares in the company, valued at $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Eric Sherbet sold 5,800 shares of the company’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.